Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · All outcomes

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Non-specific immunotherapy (recombinant interleukin-2 or BCG cell wall preparation) plus standard therapy vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Disease-free survival · People with squamous cell carcinoma of the oral cavity or oropharynx

It is very uncertain whether non-specific immunotherapy (recombinant interleukin-2 or BCG cell… changes disease-free survival compared with standard therapy alone (very low certainty).

1 finding from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
24 to 70 months · Recombinant interleukin-2 + surgery (De Stefani 2002)
HR 0.66 [0.43, 1.02]
1 study · 201 participants
Very low

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Disease-free survival · People with squamous cell carcinoma of the oral cavity or oropharynx

It is very uncertain whether tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… changes disease-free survival compared with standard therapy alone (radiotherapy or chemoradiotherapy) (very low certainty).

1 finding from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
40 to 60 months · Gefitinib + radiotherapy (oral cavity)
HR 1.51 [0.61, 3.71]
1 study · 60 participants
Very low